vs
Side-by-side financial comparison of Iterum Therapeutics plc (ITRM) and Lakeshore Acquisition III Corp. (LCCC). Click either name above to swap in a different company.
Lakeshore Acquisition III Corp. is the larger business by last-quarter revenue ($717.3K vs $390.0K, roughly 1.8× Iterum Therapeutics plc). Lakeshore Acquisition III Corp. runs the higher net margin — 67.9% vs -2302.3%, a 2370.2% gap on every dollar of revenue.
Iterum Therapeutics plc is a clinical-stage biopharmaceutical company specializing in developing innovative anti-infective therapies to treat infections caused by multi-drug resistant bacteria. Its lead product candidate targets indications including community-acquired bacterial pneumonia and complicated urinary tract infections, addressing unmet medical needs across global healthcare markets.
ITRM vs LCCC — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $390.0K | $717.3K |
| Net Profit | $-9.0M | $486.8K |
| Gross Margin | — | — |
| Operating Margin | -1982.3% | -32.1% |
| Net Margin | -2302.3% | 67.9% |
| Revenue YoY | — | — |
| Net Profit YoY | -47.3% | — |
| EPS (diluted) | $-0.20 | $0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $390.0K | $717.3K | ||
| Q2 25 | — | $467.3K |
| Q3 25 | $-9.0M | $486.8K | ||
| Q2 25 | — | $216.5K |
| Q3 25 | -1982.3% | -32.1% | ||
| Q2 25 | — | -53.7% |
| Q3 25 | -2302.3% | 67.9% | ||
| Q2 25 | — | 46.3% |
| Q3 25 | $-0.20 | $0.08 | ||
| Q2 25 | — | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.0M | — |
| Total DebtLower is stronger | $20.0M | — |
| Stockholders' EquityBook value | $-7.4M | $-1.6M |
| Total Assets | $32.5M | $71.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $11.0M | — | ||
| Q2 25 | — | — |
| Q3 25 | $20.0M | — | ||
| Q2 25 | — | — |
| Q3 25 | $-7.4M | $-1.6M | ||
| Q2 25 | — | $-1.4M |
| Q3 25 | $32.5M | $71.0M | ||
| Q2 25 | — | $70.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.4M | $-206.3K |
| Free Cash FlowOCF − Capex | $-7.5M | — |
| FCF MarginFCF / Revenue | -1912.6% | — |
| Capex IntensityCapex / Revenue | 3.1% | — |
| Cash ConversionOCF / Net Profit | — | -0.42× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-7.4M | $-206.3K | ||
| Q2 25 | — | $-218.3K |
| Q3 25 | $-7.5M | — | ||
| Q2 25 | — | — |
| Q3 25 | -1912.6% | — | ||
| Q2 25 | — | — |
| Q3 25 | 3.1% | — | ||
| Q2 25 | — | — |
| Q3 25 | — | -0.42× | ||
| Q2 25 | — | -1.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
